As per our report, the size of the global monoclonal antibodies market was worth USD 37.13 Billion in 2019. This figure is estimated to be growing at a CAGR of 5.30% and will reach USD 63.13 Billion by 2024.
In biochemistry and molecular biology, monoclonal antibodies play an important role as they can detect or purify substances. In general, these are derived from the identical immune cells and can easily bind to a particular antigen. Hybridoma technology is designing monoclonal antibodies where this will enhance the immunity system naturally. It is approved by the U.S Food and Drug Administration (FDA) as it is an innovative product in the molecular biology for disease treatment. Many global companies are focusing on the development of the molecular agents which will use for the treatment of various diseases like cancer.
MARKET DRIVERS
Increasing incidences of chronic diseases such as cancer, diabetes, and others across the world is undoubtedly a key factor for the worldwide monoclonal antibodies market to grow. The rise in the demand to ensure quality services in healthcare is additionally accelerating the need of the market. Also, the invention of new applications in monoclonal antibodies is significantly influencing the growth rate of this market to the extent. The rise in the investments in the improvement of healthcare infrastructure is likely to boost up the demand of the global mABs market. The development of new molecules is expected to play a prominent role in the future of the market due to the cost-effectiveness of this technology.
The advancement of genomics research and development activities, as well as the emergence of technologically advanced genetic platforms, such as the next-generation sequencing, has contributed significantly to the market and helping the existing companies in the global mABs market to grow further.
The emergence of advance technology and the launch of innovative products in the biotechnology field and growth in the economy in both developed and developing countries are surging the demand of the monoclonal antibodies market. Growing knowledge over genomics and trend towards next-generation sequencing and ease in the availability of various resources used in the research centres are fueling the demand of the market. The rise in the awareness over the therapies and other biological parameters are impacting positively on the growth of the market.
MARKET RESTRAINTS
However, less availability of raw materials used for the manufacturing of drugs is restraining the demand of the market. Lack of sufficient knowledge in rural areas is slowly to hinder the growth rate of the market.
Some of the other major challenging factors for the monoclonal antibodies market is the shortage of skilled labour. It is due to less training programs in the biotechnology field. The equipment used in the laboratories is high in cost where small scale organizations cannot afford them, which is also one of the factors impeding the demand of the mABs market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Source, Indication, End User, Application and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on Global Monoclonal Antibodies Market has been segmented and sub-segmented based on the source, indication, end-user, application and region.
Monoclonal Antibodies Market - By Source
Based on the source, the murine segment is holding the highest shares of the global monoclonal antibodies market, whereas chimeric is to have the highest growth rate in the coming years. An increasing number of people suffering from various health disorders is a specific factor for this segment to grow.
Monoclonal Antibodies Market - By Indication
Based on indication, the cancer disease segment is ruling with dominant shares of the global mABs market. Adoption of sedentary lifestyles and changes in food habits are some of the attributes for cancer diseases category to grow.
Monoclonal Antibodies Market - By End-User
Based on end-user, Hospitals/clinics have the most significant shares in the market by owing to the increase in the scale of healthcare centres and clinics. Besides, the growing geriatric population is enhancing the growth rate of the market.
Monoclonal Antibodies Market - By Application
Based on application, the medical segment is holding dominant shares of the global monoclonal antibodies market due to a rise in the number of research and development activities.
Regional Analysis:
North America is dominating the market due to the existence of well-established health care infrastructure in this region, the increased importance given to state infection control and management and the growing prevalence of lifestyle-related health issues. During the forecast period, the market will continue to grow, owing to amplified public investments for cancer research and technological development.
Asia-Pacific market segment is also anticipated to increase significantly due to improved lifestyles of people and increasing awareness about mAbs among patients, increased research and development costs. Due to the lack of penetration, the Asia Pacific market has a high potential to grow during the forecast period.
TOP COMPANIES IN THE MARKET
Companies leading the global monoclonal antibodies market profiled in the report are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. And Shanghai Junshi Bioscience Co., Ltd.
RECENT MARKET DEVELOPMENTS
In January 2020, Pfizer has announced to launch Bavencio (avelumab) vaccine which is used to treat cancer patients.
In February 2020, GlaxoSmithKline plc has registered to introduce belantamab mafodotin which will act upon the B-cell maturation antigen.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Indication
5.2.1 Cancer
5.2.1.1 Blood Cancer
5.2.1.2 Breast Cancer
5.2.1.3 Colorectal Cancer
5.2.1.4 Lung Cancer
5.2.1.5 Pancreatic Cancer
5.2.1.6 Others
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 Seattle Genetics (U.S.)
9.7 Bristol-Myers Squibb (U.S.)
9.8 F. Hoffmann-La Roche Ltd. (Switzerland)
9.9 Biogen Inc.(U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
